New

Long Acting Injectable Medications Market

2021

Long Acting Injectable Medications Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type (First Generation, and Second Generation); End Use (Schizophrenia, Contraception, HIV, and Others), and Geography

| Report Code: TIPRE00023213 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Market Insights

Long Acting Injectable Medications Market 2028 By Type, End Use, and Geography | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Long-acting injectables (LAIs) are unique medicines used in psychiatric pharmacies to help improve patient outcomes. They offer several benefits compared to oral therapy, including confirmed patient adherence, consistent drug delivery, predictable bioavailability, and prevention of antipsychotic overdoses. Its origins in indications such as schizophrenia and contraception, also HIV treatment and prevention.

MARKET SCOPE

The "Global Long-Acting Injectable Medications Market Analysis to 2028" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Long-acting injectable medications market with detailed market segmentation by type, end use, and geography. The report provides key statistics on the market status of the leading Long-acting injectable medications market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •  Based on type, the global Long-acting injectable medications market is segmented into first generation, second generation.
  •  On the basis of end use, the market is segmented into schizophrenia, contraception, hiv, others.

MARKET DYNAMICS
Drivers

  •   Provides significant clinical advantages like patient compliance, reduced hospitalization.
  •   Increased use in schizophrenia.
  •   Favorable reimbursement policies.

Restraints

  •   The side effects associated with long-acting injectable medications is the major restraining factor for this market.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Long-acting injectable medications market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Long-acting injectable medications market in these regions.

IMPACT OF COVID-19 ON LONG-ACTING INJECTABLE MEDICATIONS MARKET

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Long-acting injectable medications market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Long-acting injectable medications market are anticipated to lucrative growth opportunities in the future with the rising demand for Long-acting injectable medications in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Long-acting injectable medications market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  Eli Lilly
  •  Alkermes
  •  Johnson and Johnson
  •  Zogenix
  •  DURECT
  •  Mapi Pharma
  •  GSK
  •  MedinCell
  •  Oakwood Labs
  •  Nanomi

The Insight Partner's dediLong-acting injectable medicationsed research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Long Acting Injectable Medications Market - By Type
1.3.2 Long Acting Injectable Medications Market - By End Use
1.3.3 Long Acting Injectable Medications Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. LONG ACTING INJECTABLE MEDICATIONS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. LONG ACTING INJECTABLE MEDICATIONS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. LONG ACTING INJECTABLE MEDICATIONS MARKET - GLOBAL MARKET ANALYSIS
6.1. LONG ACTING INJECTABLE MEDICATIONS - GLOBAL MARKET OVERVIEW
6.2. LONG ACTING INJECTABLE MEDICATIONS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. LONG ACTING INJECTABLE MEDICATIONS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. FIRST GENERATION
7.3.1. Overview
7.3.2. First Generation Market Forecast and Analysis
7.4. SECOND GENERATION
7.4.1. Overview
7.4.2. Second Generation Market Forecast and Analysis
8. LONG ACTING INJECTABLE MEDICATIONS MARKET - REVENUE AND FORECASTS TO 2028 - END USE
8.1. OVERVIEW
8.2. END USE MARKET FORECASTS AND ANALYSIS
8.3. SCHIZOPHRENIA
8.3.1. Overview
8.3.2. Schizophrenia Market Forecast and Analysis
8.4. CONTRACEPTION
8.4.1. Overview
8.4.2. Contraception Market Forecast and Analysis
8.5. HIV
8.5.1. Overview
8.5.2. HIV Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. LONG ACTING INJECTABLE MEDICATIONS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Long Acting Injectable Medications Market Overview
9.1.2 North America Long Acting Injectable Medications Market Forecasts and Analysis
9.1.3 North America Long Acting Injectable Medications Market Forecasts and Analysis - By Type
9.1.4 North America Long Acting Injectable Medications Market Forecasts and Analysis - By End Use
9.1.5 North America Long Acting Injectable Medications Market Forecasts and Analysis - By Countries
9.1.5.1 United States Long Acting Injectable Medications Market
9.1.5.1.1 United States Long Acting Injectable Medications Market by Type
9.1.5.1.2 United States Long Acting Injectable Medications Market by End Use
9.1.5.2 Canada Long Acting Injectable Medications Market
9.1.5.2.1 Canada Long Acting Injectable Medications Market by Type
9.1.5.2.2 Canada Long Acting Injectable Medications Market by End Use
9.1.5.3 Mexico Long Acting Injectable Medications Market
9.1.5.3.1 Mexico Long Acting Injectable Medications Market by Type
9.1.5.3.2 Mexico Long Acting Injectable Medications Market by End Use
9.2. EUROPE
9.2.1 Europe Long Acting Injectable Medications Market Overview
9.2.2 Europe Long Acting Injectable Medications Market Forecasts and Analysis
9.2.3 Europe Long Acting Injectable Medications Market Forecasts and Analysis - By Type
9.2.4 Europe Long Acting Injectable Medications Market Forecasts and Analysis - By End Use
9.2.5 Europe Long Acting Injectable Medications Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Long Acting Injectable Medications Market
9.2.5.1.1 Germany Long Acting Injectable Medications Market by Type
9.2.5.1.2 Germany Long Acting Injectable Medications Market by End Use
9.2.5.2 France Long Acting Injectable Medications Market
9.2.5.2.1 France Long Acting Injectable Medications Market by Type
9.2.5.2.2 France Long Acting Injectable Medications Market by End Use
9.2.5.3 Italy Long Acting Injectable Medications Market
9.2.5.3.1 Italy Long Acting Injectable Medications Market by Type
9.2.5.3.2 Italy Long Acting Injectable Medications Market by End Use
9.2.5.4 Spain Long Acting Injectable Medications Market
9.2.5.4.1 Spain Long Acting Injectable Medications Market by Type
9.2.5.4.2 Spain Long Acting Injectable Medications Market by End Use
9.2.5.5 United Kingdom Long Acting Injectable Medications Market
9.2.5.5.1 United Kingdom Long Acting Injectable Medications Market by Type
9.2.5.5.2 United Kingdom Long Acting Injectable Medications Market by End Use
9.2.5.6 Rest of Europe Long Acting Injectable Medications Market
9.2.5.6.1 Rest of Europe Long Acting Injectable Medications Market by Type
9.2.5.6.2 Rest of Europe Long Acting Injectable Medications Market by End Use
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Long Acting Injectable Medications Market Overview
9.3.2 Asia-Pacific Long Acting Injectable Medications Market Forecasts and Analysis
9.3.3 Asia-Pacific Long Acting Injectable Medications Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Long Acting Injectable Medications Market Forecasts and Analysis - By End Use
9.3.5 Asia-Pacific Long Acting Injectable Medications Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Long Acting Injectable Medications Market
9.3.5.1.1 Australia Long Acting Injectable Medications Market by Type
9.3.5.1.2 Australia Long Acting Injectable Medications Market by End Use
9.3.5.2 China Long Acting Injectable Medications Market
9.3.5.2.1 China Long Acting Injectable Medications Market by Type
9.3.5.2.2 China Long Acting Injectable Medications Market by End Use
9.3.5.3 India Long Acting Injectable Medications Market
9.3.5.3.1 India Long Acting Injectable Medications Market by Type
9.3.5.3.2 India Long Acting Injectable Medications Market by End Use
9.3.5.4 Japan Long Acting Injectable Medications Market
9.3.5.4.1 Japan Long Acting Injectable Medications Market by Type
9.3.5.4.2 Japan Long Acting Injectable Medications Market by End Use
9.3.5.5 South Korea Long Acting Injectable Medications Market
9.3.5.5.1 South Korea Long Acting Injectable Medications Market by Type
9.3.5.5.2 South Korea Long Acting Injectable Medications Market by End Use
9.3.5.6 Rest of Asia-Pacific Long Acting Injectable Medications Market
9.3.5.6.1 Rest of Asia-Pacific Long Acting Injectable Medications Market by Type
9.3.5.6.2 Rest of Asia-Pacific Long Acting Injectable Medications Market by End Use
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Long Acting Injectable Medications Market Overview
9.4.2 Middle East and Africa Long Acting Injectable Medications Market Forecasts and Analysis
9.4.3 Middle East and Africa Long Acting Injectable Medications Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Long Acting Injectable Medications Market Forecasts and Analysis - By End Use
9.4.5 Middle East and Africa Long Acting Injectable Medications Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Long Acting Injectable Medications Market
9.4.5.1.1 South Africa Long Acting Injectable Medications Market by Type
9.4.5.1.2 South Africa Long Acting Injectable Medications Market by End Use
9.4.5.2 Saudi Arabia Long Acting Injectable Medications Market
9.4.5.2.1 Saudi Arabia Long Acting Injectable Medications Market by Type
9.4.5.2.2 Saudi Arabia Long Acting Injectable Medications Market by End Use
9.4.5.3 U.A.E Long Acting Injectable Medications Market
9.4.5.3.1 U.A.E Long Acting Injectable Medications Market by Type
9.4.5.3.2 U.A.E Long Acting Injectable Medications Market by End Use
9.4.5.4 Rest of Middle East and Africa Long Acting Injectable Medications Market
9.4.5.4.1 Rest of Middle East and Africa Long Acting Injectable Medications Market by Type
9.4.5.4.2 Rest of Middle East and Africa Long Acting Injectable Medications Market by End Use
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Long Acting Injectable Medications Market Overview
9.5.2 South and Central America Long Acting Injectable Medications Market Forecasts and Analysis
9.5.3 South and Central America Long Acting Injectable Medications Market Forecasts and Analysis - By Type
9.5.4 South and Central America Long Acting Injectable Medications Market Forecasts and Analysis - By End Use
9.5.5 South and Central America Long Acting Injectable Medications Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Long Acting Injectable Medications Market
9.5.5.1.1 Brazil Long Acting Injectable Medications Market by Type
9.5.5.1.2 Brazil Long Acting Injectable Medications Market by End Use
9.5.5.2 Argentina Long Acting Injectable Medications Market
9.5.5.2.1 Argentina Long Acting Injectable Medications Market by Type
9.5.5.2.2 Argentina Long Acting Injectable Medications Market by End Use
9.5.5.3 Rest of South and Central America Long Acting Injectable Medications Market
9.5.5.3.1 Rest of South and Central America Long Acting Injectable Medications Market by Type
9.5.5.3.2 Rest of South and Central America Long Acting Injectable Medications Market by End Use
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL LONG ACTING INJECTABLE MEDICATIONS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. LONG ACTING INJECTABLE MEDICATIONS MARKET, KEY COMPANY PROFILES
12.1. ELI LILLY
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ALKERMES
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. JOHNSON AND JOHNSON
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ZOGENIX
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. DURECT
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MAPI PHARMA
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. GSK
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. MEDINCELL
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. OAKWOOD LABS
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. NANOMI
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Eli Lilly
2. Alkermes
3. Johnson and Johnson
4. Zogenix
5. DURECT
6. Mapi Pharma
7. GSK
8. MedinCell
9. Oakwood Labs
10. Nanomi
11. Pharmathen
12. Kashiv BioSciences
TIPRE00023213
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.